Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

This year’s forum will focus on the importance of collaboration for expanding Ireland’s STEM pipeline. Broadcaster Áine Kerr will ... including the Department of Education, Analog Devices, Amgen, RTE, ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Robert Bradway, chairman and CEO said, “Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Analysts note that while the base business remains resilient, the focus has shifted to Amgen's pipeline and potential growth drivers. The integration of the Horizon franchise, bolstered by Tepezza ...

Analysts note that while the base business remains resilient, the focus has shifted to Amgen's pipeline and potential growth drivers. The integration of the Horizon franchise, bolstered by Tepezza's ...

Beyond MariTide, Amgen's pipeline includes several other promising candidates: Uplizna: Recently showed favorable Phase III results for generalized myasthenia gravis (gMG) Rocatinlimab: In development ...